Loading publications…
The last 5 uploaded publications
251 WNT-PATHWAY ACTIVATION IN TWO MOLECULAR CLASSES OF HEPATOCELLULAR CARCINOMA AND EXPERIMENTAL MODULATION BY SORAFENIB
Anja Lachenmayer, Clara Alsinet, Radoslav Savić, Laia Cabellos, S. Toffanin, Yujin Hoshida, A. Villanueva, Beatriz Mínguez, Pippa Newell, Hsin‐Tzu Tsai, Jordi Barretina, S N Thung, Stephen C. Ward, Jordi Bruix, Vincenzo Mazzaferro, M. Schwartz, Scott L. Friedman, Josep M. Llovet (2012). 251 WNT-PATHWAY ACTIVATION IN TWO MOLECULAR CLASSES OF HEPATOCELLULAR CARCINOMA AND EXPERIMENTAL MODULATION BY SORAFENIB. Journal of Hepatology, 56, pp. S106-S106, DOI: 10.1016/s0168-8278(12)60264-5.
Article146 days agoMolecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial
Roser Pinyol, Robert Montal, T. Takayama, Gar‐Yang Chau, Vincenzo Mazzaferro, S. Roayaie, H.C. Lee, Rtp Poon, N. Kokudo, Z. Zhang, Laia Bassaganyas, Sara Torrecilla, Agrin Moeini, Leonardo Rodríguez‐Carunchio, Edward Gane, Chris Verslype, Adina Croitoru, Umberto Cillo, Manuel de la Mata, L. Lupo, Simone I. Strasser, J.-W. Park, Jordi Camps, María A. Solé, S N Thung, A. Villanueva, Carol E. Peña, G. Meinhart, Jordi Bruix, Josep M. Llovet (2017). Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial. Journal of Hepatology, 66(1), pp. S12-S13, DOI: 10.1016/s0168-8278(17)30287-8.
Article146 days agoRe-Expression of Fetal Igf2 as Epidriver and Target for Therapy in Hcc
Iris Martinez-Quetglas, Roser Pinyol, Daniel Dauch, Sara Torrecilla, Victoria Tovar, Agrin Moeini, Clara Alsinet, Silvana Bonilla, Anna Portela, Leonardo Rodríguez‐Carunchio, María A. Solé, A. Villanueva, Manel Esteller, Lars Zender, Josep M. Llovet (2016). Re-Expression of Fetal Igf2 as Epidriver and Target for Therapy in Hcc. Journal of Hepatology, 64(2), pp. S158-S158, DOI: 10.1016/s0168-8278(16)01663-9.
Article146 days agoMolecular characterization of the immune class of hepatocellular carcinoma
Iris Martinez-Quetglas, Daniela Sia, Yu Jiao, O. Kuchuck, Carlos Villacorta Martin, Manuel Castro de Moura, Juan Putra, Genís Campreciós, S N Thung, Vincenzo Mazzaferro, Manel Esteller, A. Villanueva, Josep M. Llovet (2017). Molecular characterization of the immune class of hepatocellular carcinoma. Journal of Hepatology, 66(1), pp. S465-S466, DOI: 10.1016/s0168-8278(17)31317-x.
Article146 days ago2 DISRUPTION OF IGF SIGNALING IN EARLY HEPATOCELLULAR CARCINOMA AND PRE-CLINICAL EFFICACY OF ANTI-IGF1R BLOCKING THERAPIES
Victoria Tovar, Clara Alsinet, Laia Cabellos, María A. Solé, A. Villanueva, Derek Y. Chiang, Susana Moyano, M. Schwartz, Vincenzo Mazzaferro, Jordi Bruix, Josep M. Llovet (2008). 2 DISRUPTION OF IGF SIGNALING IN EARLY HEPATOCELLULAR CARCINOMA AND PRE-CLINICAL EFFICACY OF ANTI-IGF1R BLOCKING THERAPIES. Journal of Hepatology, 48, pp. S3-S3, DOI: 10.1016/s0168-8278(08)60004-5.
Article146 days ago